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Nephrogenic systemic fibrosis: a serious late
adverse reaction to gadodiamide
Recently, it has been reported [1, 2]
that a serious adverse reaction called
nephrogenic systemic fibrosis (NSF)
may occur after exposure to the
extracellular nonionic low osmolar
gadolinium-based contrast agent
gadodiamide (Omniscan
®, GE Health
Diagnostic, Amersham, United King-
dom). Nephrogenic systemic fibrosis
was recognized in 1997 in California
[3]. The typical patient is middle-aged
and has end-stage renal disease
(ESRD) [4]. Most patients, but not all,
are on regular dialysis treatment. The
typical course begins with subacute
swelling of distal parts of the extrem-
ities followed during subsequent
weeks by severe skin induration and
sometimes anatomical extension
involving thighs, antebrachium, and
lower abdomen. The skin induration
may be aggressive and associated with
constant pain, muscle restlessness, and
loss of skin flexibility. In some cases,
NSF leads to serious physical disabil-
ity including wheelchair requirement.
NSF was initially observed in and
thought to solely affect the skin—
therefore, it was initially called neph-
rogenic fibrosing dermopathy—but it
is now known that several organs such
as liver, lungs, muscles and heart may
be involved. Organ involvement may
explain the suspected increased mor-
tality of NSF patients [4].
Grobner was the first to propose
that MR contrast media containing Gd
might be a trigger of NSF [2].
Marckmann [1] reported 13 patients
who had been exposed to gadodi-
amide prior to the development of
NSF. The authors could not identify
any other common exposure/event.
Thedelayfromexposuretofirstsignof
the disease was 2–75 days (median
25 days). Odds ratio for acquiring the
disease if gadodiamide-exposed was
32.5 (95% CI: 1.9–549.2) (p<0.0001).
Seven patients (54%) became severely
disabled and one died 21 months after
exposure. Evenepoel et al. reported
already in 2004 two cases of severe
NSF[5].Acommonfactorforthethree
European reports is that all 20 patients
had had gadodiamide ([6]; Oyen, per-
sonal communication, August 2006).
The official site of the nephrogenic
fibrosing dermopathy (NFD/NSF)
registry[3]statesthatallregistrycases,
in which records can be located, have
at least one known exposure to gado-
linium within 2 to 8 weeks prior to
clinical symptoms. However, it is not
mentioned to which gadolinium-based
contrast agent the patients had been
exposed.Inapersonalcommunication,
Dr. Cowper writes that the registry has
information that the majority had had
gadodiamide.
In August 2006, all members of the
European Society of Urogenital Ra-
diology (ESUR) received an electron-
ic mail asking them to report cases of
NSF to the chairman of the ESUR
contrast media safety committee in
request for material for the upcoming
meeting of the committee. The com-
plete material will be analyzed, but
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responses were obvious: (1) I have
never heard about NSF (most frequent
answer); (2) we have never seen a case
of NSF; (3) yes, we have seen cases of
NSF after administration of Gd-based
contrast media. If the answer belonged
to group 2 or 3, the responder was
asked which contrast agent they had
used. In Europe, it turned out that all
patients who developed NSF had had
gadodiamide within a few weeks
before developing NSF. In the US, the
overwhelming majority of patients
who had had a gadolinium agent had
had gadodiamide. Four patients may
have had oneof the other agents with a
linear chelate (gadoversetamide and
gadopentate dimeglumine). It was
unclear what the rest had had; it will
be checked, but it may be difficult as
some of the examinations took place
outside the contacted institution and
some had multiple injections of var-
ious agents.
Based on the obtained information,
it seems appropriate to draw the
following conclusions:
(1) It is striking that many radiolo-
gists were unaware that nephro-
genic systemic fibrosis may be a
serious late adverse reaction to
gadolinium-based contrast media
despite the fact that the Food and
Drug Administration issued a
warning 8 June 2006 [7].
Furthermore, the warning from
the vendor of gadodiamide issued
6 June 2006 [8] had not been
distributed in several countries.
No other vendors have issued a
warning.
(2) More than 150 patients have de-
veloped NSF after exposure to a
Gd-based contrast medium. The
overwhelming majority (∼90%)
had had gadodiamide with cer-
tainty. Regarding the remaining
patients it is still unknown what
they had. At least three patients,
who developed NSF, had gado-
diamide after 8 June 2006. Two
patients got it in August 2006.
(3) NSF after exposure to gadodi-
amide has been seen in Cauca-
sian and Afro-Americans. It has
been observed also in the United
Kingdom, USA, the Netherlands,
France, Belgium, Austria and
Denmark. The patients were either
on dialysis or had reduced renal
function (highest GFR reported:
20 ml/min.).
(4) There are no reports of NSF in
patients with normal kidney
function. Around 200 million
patients have had injections of a
gadolinium-based contrast agent
since the early 1980s. A popula-
tion of more than 30 million
patients has received gadodi-
amide. So, in patients without
ESRD, all gadolinium-based con-
trast agents seem to be safe.
(5) Exposure to a gadolinium-based
contrast agent cannot be docu-
mented in all patients developing
NSF.
Gadodiamide is almost exclusively
excreted renally and therefore has a
markedly prolonged half-life in renal
failure patients, including dialysis
patients [9]. The molecular structure
of chelate (DTPA-BMA) binding Gd
is linear. Gadodiamide formulation
differs from most other non-tissue
specific extracellular MR imaging
agents on the European market by
having an excess chelate (12 mg/ml)
and being less stabile [9]. The excess
chelate is considered necessary be-
cause of the possibility of transmetal-
lation with endogenous ions [9].
Transmetallation results in release of
free Gd
+++, which is extremely toxic,
but it can also cause binding of other
ions. Agents susceptible to transme-
tallation have the largest amount of
excess chelate. Thus, it seems possible
that transmetallation is easier with
gadodiamide than in other gadolini-
um-based contrast agents [10]. Of
course, transmetallation is more likely
to occur when gadolinium-based
agents remain inside the body for a
long period as is the case in patients
with renal failure. Whether transme-
tallation plays a crucial role in the
development of NSF in patients with
renal failure remains unproven [1].
Several NSF cases reported by
Marckmann [1] were exposed to
gadodiamide earlier without develop-
ing signs of NSF. This observation
suggests that gadodiamide was a
necessary, but not a sufficient cause of
NSF. Certain other factors must have
played a role, but they were not able to
identify any such cofactor. Also, the
fact that NSF can develop in patients
in whom it cannot be documented that
they have had a gadolinium-based
agent speaks in favour of a cofactor.
NSF is a serious late adverse reac-
tion in patients with end-stage renal
failure or on dialysis. Recently pub-
lished reports [1, 2, 5] and a simple
and rapid survey suggest a possible
causal relationship between gadodi-
amide and NSF. Whether other gado-
linium-based contrast agents can
trigger the development of NSF is not
yet clear. There are no published
reports at the time of writing (Sep-
tember 2006). Careful analyses of the
current data as well as new research
are strongly warranted. All radiolo-
gists should be informed about this
serious late adverse reaction. Cases
with a positive history of exposure to
gadolinium-based contrast agents
should be reported to the National
Medicines Agencies. The ESUR
Contrast Media Safety Committee
(http://www.esur.org) will appreciate
receiving information. Adverse events
to gadolinium contrast agents can
also be reported at http://www.fda.
gov/medwatch/index.html.A tt h i s
stage, based on the available informa-
tion, gadodiamide should not be
administered to patients with renal
impairment,includingthoseondialysis.
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